|Articles|September 1, 2001

September 2001
Volume 7
Issue 9

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Author(s)A. Mark Fendrick, MD, Dean G. Smith, PhD, Michael E. Chernew, PhD

Download PDF: A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Articles in this issue

almost 25 years ago

Article

Effect of Moderate Weight Loss on Health-Related Quality of Life: An Analysis of Combined Data From 4 Randomized Trials of Sibutramine vs Placebo

almost 25 years ago

Article

A Randomized Intervention to Improve Ongoing Participation in Mammography

almost 25 years ago

Article

Impact of a Targeted Asthma Intervention Program on Treatment Costs in Patients with Asthma

almost 25 years ago

Article

Comparison of Prevalence, Cost, and Outcomes of a Combination of Salmeterol and Fluticasone Therapy to Common Asthma Treatments

almost 25 years ago

Article

Weight Loss and Health-Related Quality of Life

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

Rituximab Matches Ocrelizumab in Head-to-Head MS Trial